“However, expect given the current dynamics in China, that is it is not so likely that we will ship further products in China, and that is actually an outcome that is incorporated into the midpoint of our guidance.”

In context

“hank you, Steve, for the question. First, the information that we're providing with regards to the opportunities to grow Dartasil outside of China is not new. What we are highlighting, however, is a very effective execution by our colleagues in Japan of a catch-up cohort program that ends on the March 31 of this year. And as a result of that ending, we expect ourselves in just Japan to reflect the primary age cohort and therefore be reduced from quarter two onwards to what we have achieved over the prior quarters. As we look to Gardasil globally this year, we expect China to be a headwind. We had said previously with regards to China, we will assess do we or do we not ship further products this year at the midpoint of this year? And we will do that assessment at the midpoint of this year. However, expect given the current dynamics in China, that is it is not so likely that we will ship further products in China, and that is actually an outcome that is incorporated into the midpoint of our guidance. All of that said, we do expect strong growth excluding China, strong double-digit we've achieved in the first quarter and we expect continued strong growth as we go through the remainder of the year. In terms of the longer-term guidance, we did withdraw the $11 billion target last quarter given the fact that China was an important part of the achievement of that $11 billion. Our company remains focused and on the ground in China to maximize the opportunity and maximize the launch in males while we're working across the entirety of the world to protect many more lives from HPV-related cancers and drive growth for our business as we move forward. Peter Dannenbaum: Great. Thanks, Steve. Next question, please. Alex Hammond: Next question is from Alex Hammond from Wolfe Research. Go ahead. You”